Preclinical study demonstrates that EGCG suppresses gastric cancer tumor growth and invasion by inhibiting Hedgehog signaling, suggesting a potential low-toxicity therapeutic strategy.
Gastric cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for effective and low-toxic therapeutic alternatives. This study investigated the antitumor efficacy of Epigallocatechin gallate (EGCG) in gastric cancer, focusing on the Hedgehog signaling pathway. In HGC27 cells, EGCG treatment inhibited proliferation, colony formation, migration, and invasion in a dose- and time-dependent manner. In a nude mouse xenograft model, oral administration of EGCG (10–50 mg/kg) significantly suppressed tumor growth, achieving an 84.2% reduction in tumor volume in the high-dose group, accompanied by favorable histopathological changes. Mechanistically, EGCG downregulated core Hedgehog pathway proteins (Shh, Gli1, Ptch1) and downstream effectors, Cyclin D1 and MMP-9, in both in vitro and in vivo models. In conclusion, EGCG exhibits robust anti-proliferative and anti-metastatic activity in gastric cancer HGC27 cells by blocking Hedgehog signaling. These findings provide a compelling preclinical rationale for developing EGCG-based therapeutic strategies targeting the Hedgehog pathway for gastric cancer treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: